Drug Pipeline Update

New drug information

- **RoxyBond™ (oxycodone hydrochloride):** The Food and Drug Administration (FDA) approved Inspirion’s Roxybond for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Roxybond is an immediate release formulation of oxycodone that uses physical and chemical barriers to deter abuse. Roxybond has increased resistance to several types of manipulation; however, abuse by intranasal, oral, and IV route is still possible.¹

- **Xatmep™ (methotrexate) oral solution:** Silvergate Pharmaceuticals received FDA approval for Xatmep, the first ready-to-use methotrexate oral solution for the treatment of acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients.

New generics

- **Topicort® (desoximetasone 0.05%) ointment:** Lupin Pharmaceuticals launched the first generic of Taro’s Topicort 0.05% ointment for the relief of inflammatory and itchy corticosteroid-responsive skin conditions.

- **Vytorin® (ezetimibe/simvastatin):** Generic versions of Merck/Schering-Plough’s Vytorin for the treatment of high cholesterol have launched. The following manufacturers have launched generic versions of Vytorin: Impax Generics, Dr. Reddy’s Laboratories, and Actavis/Teva. In addition, Mylan may launch their generic version in the second quarter of 2017. According to IMS, Vytorin had approximately $678 million in sales over the past year.

- **Seroquel® XR (quetiapine fumarate):** Trupharma has launched the first true generic of Astrazeneca’s Seroquel XR for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Par Pharmaceuticals had previously launched an authorized generic version in November 2016 and AstraZeneca launched its authorized generic in May. Several other generics are anticipated to launch in the second quarter of 2017. According to IMS, Seroquel XR had approximately $911 million in sales over the past year.

References


All brand names are property of their respective owners.

While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.